vTv Therapeutics to Detail Potential Alzheimer’s Treatment, Now in Phase 3 Study, at Meeting Today

vTv Therapeutics to Detail Potential Alzheimer’s Treatment, Now in Phase 3 Study, at Meeting Today
Larry Altstiel, MD, PhD, chief medical officer of vTv Therapeutics, will speak today on the panel “Novel Approaches to Alzheimer’s Disease,” during the Neuro Advance Boston conference hosted by Harvard Medical School. Altstiel will detail the mechanisms of action of azeliragon, vTv Therapeutics' investigative treatment for mild Alzheimer’s disease (AD), in his Oct. 5 presentation, according to a press release. The treatment is currently in a Phase 3 clinical trial in people with mild Alzheimer's, which is recruiting patients.
Subscribe or to access all post and page content.